About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More

NCT00813956

A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (PARPInhibitor also known as iniparib) in the Neoadjuvant Treatment of Triple Negative (or BRCA Positive) Breast Cancer

Update: This study is no longer recruiting patients.

Study identifier: NCT00813956
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Iniparib (Sanofi Aventis)

Eligibility:

Open to patients with a BRCA mutation or triple-negative breast cancer. Must have stage I-IIIA invasive breast cancer and have received no prior treatment for their breast cancer. Must still have tumor which must be at least 1 cm in diameter.

Type of study:

Phase II study

Treatment:

Participants receive a combination of iniparib, gemcitibine and carboplatin. 

Study site:

Update: This study is no longer recruiting patients.

Page updated 06/13/13

Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us

Morphtek

This site has been made possible by a generous grant from Morphotek.


Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org